Barry Ticho sold $27k of STOK
CHIEF MEDICAL OFFICER at Stoke Therapeutics, Inc.. 1,051 shares at an average of $26.16, traded Oct 1, 2026, filed Oct 2, 2026.
Score components
- +15RoleOfficer
- +5Trade size$27k at market
- 0Share of holdings soldSold 5.2% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001780088-26-000023, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -1,051 | $26.16 | $27k | 19,059 | 10 d ago |
Related signals
Other insiders at Stoke Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $17k 627 shares | -3% | |
| 11Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $170k 5,545 shares | -22% | |
| 25Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $445k 22,117 shares | -89% | |
| 38Weak | Stoke Therapeutics, Inc. | Edward M. Kaye MD CEO | $1.2M 61,885 shares | -40% | |
| 28Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $31k 1,683 shares | -7% | |
| 35Weak | Stoke Therapeutics, Inc. | Edward M. Kaye MD CEO | $221k 12,126 shares | -7% | |
| 25Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $206k 13,712 shares | -41% | |
| 55Moderate | Stoke Therapeutics, Inc. | Skorpios Trust owner | $31M 3,000,000 shares | -43% | |
| 17Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $82k 8,216 shares | -24% | |
| 18Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $267k 26,631 shares | -44% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.